We proudly support the scientific community by providing investigators with funding opportunities for research that aligns with our therapeutic areas of interest.
By providing granting opportunities to investigators, Taiho is firmly committed to forwarding scientific research that increases our understanding of scientific and clinical aspects of disease and therapeutics, improving medical care, promoting better healthcare delivery, and providing benefits to patients.
Investigator Initiated Trial (IIT) refers to an unsolicited clinical trial proposed and sponsored by an Investigator at a hospital, medical centre, medical school, private foundation, private practice, group practice, or government-sponsored research network. IITs are unique, novel, and scientifically valid research evaluating unmet medical needs.
Applications for support may be submitted through our online portal. https://iit.taihooncology.com/IIT/
All IITs must meet the following requirements in order to receive funding or support from Taiho:
Research priorities, information regarding the application process, and approval criteria for IITs are communicated by Taiho Medical Affairs personnel to healthcare providers. Upon receiving an unsolicited request, Medical Affairs personnel may provide general advice on draft proposals, however, the proposal must be completed by healthcare providers.
Investigators are also responsible for all trial‑related medical decisions, monitoring the study, and ensuring that adequate medical care is provided for Adverse Events (AE). While Taiho reserves the right to review any manuscripts or presentations resulting from an IIT prior to submission, investigators will determine how the results of the IIT are publicized.
Taiho will only provide funding and support in accordance with an approved proposal and fully executed contract. Any Investigator who wishes to request additional support for an ongoing IIT or seek a modification of the executed contract must seek prior written approval from the IIT Review Committee. Taiho may withdraw support if an Investigator fails to comply with applicable Legal and/or regulatory obligations or provided false information in the proposal, or as otherwise specified in the contract. Taiho may not increase or decrease funding or support amounts depending on whether or not the IIT results reflect favorably upon Taiho products or any competitor products.
You are now leaving Taiho Pharma Canada’s website.
Taiho Pharma Canada assumes no responsibility for, nor does it endorse any aspect of your use of any third party sites.
Thank you for visiting our site.Continue